Memory Pharmaceuticals Corp. (Nasdaq: MEMY) 34.3% LOWER; today announced its experimental drug for Alzheimer\'s disease, MEM 1003, failed to meet ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE